v3.2.0.727

Condensed Statements of Operations (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Income Statement [Abstract]
REVENUES
OPERATING EXPENSES
General and administrative	$ 69,728	$ 6,700	$ 120,267	$ 14,460
Professional fees	103,495	227,719	220,661	231,970
Research and development	193,141	616,750	409,645	746,538
Salaries and wages	81,382	107,745	149,269	164,318
Total Operating Expenses	(447,746)	(958,913)	(899,842)	(1,157,285)
OPERATING LOSS	(447,746)	$ (958,913)	(899,842)	$ (1,157,285)
OTHER INCOME (EXPENSE)
Other Income	5,240		23,641
Foreign currency loss	1,802		(9,984)
Interest income	22	$ 200	39	$ 397
Total Other Income (Expense)	7,064	200	13,696	397
NET LOSS BEFORE INCOME TAXES	$ (440,682)	$ (958,713)	$ (886,146)	$ (1,156,889)
Provision for income taxes
NET LOSS	$ (440,682)	$ (958,713)	$ (886,146)	$ (1,156,889)
PREFERRED STOCK DIVIDEND	(189,078)	(958,713)	(366,409)	(155,769)
NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS	$ (629,760)	$ (958,713)	$ (1,252,555)	$ (1,156,889)
BASIC AND DILUTED LOSS PER SHARE	$ (0.04)	$ (0.07)	$ (0.09)	$ (0.09)
WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING	14,163,887	12,877,500	14,163,887	12,877,500

Amount of paid and unpaid preferred stock dividends declared with the form of settlement in stock.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 405

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

SignPath Pharma, Inc. 10-Q